ALEXANDRIA, Va. – Findings on a scoring algorithm for predicting the risk of developing metastatic or fatal prostate cancer will be highlighted in the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium’s official Press Program. Studies featured in the Press Program are among the nearly 600 abstracts that will be presented at the Symposium. 

The 2022 ASCO Genitourinary Cancers Symposium, taking place February 17-19 in San Francisco, CA, and online, will bring together oncology professionals from around the globe for presentations and discussions surrounding new, innovative findings in genitourinary cancer treatment, research, and care.

Abstracts will be publicly released on ASCO.org on Monday, February 14, at 5:00 p.m. ET and the embargo will lift at that time. The following abstract will be highlighted in a press release as a part of the Press Program: 

• Evaluating a polygenic hazard score to predict risk of developing metastatic or fatal prostate cancer in the multi-ancestry Million Veteran Program cohort. (Abstract 155) 

MEDIA RESOURCES  

Apply for/renew ASCO media credentials: Reporters with valid ASCO media credentials will be able to access embargoed press materials and view online presentations from the 2022 ASCO Genitourinary Cancers Symposium. Please visit ASCO’s Media Headquarters at mediahq.asco.org to request credentials or to ensure your credentials are up to date.  

Attend the Symposium in person: Credentialed media who would like to attend the meeting in-person can contact Rachel Cagan at rachel.cagan@asco.org to register. All in-person attendees must be fully vaccinated (including required booster) against COVID-19. Visit our Health and Safety page for more details.